Bioavailability of a silybin-phosphatidylcholine complex in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 30, Issue 2, 2007, Pages 132-138

  Filburn, C R ^a   Kettenacker, R ^a   Griffin, D W ^a  

^a NUTRAMAX LABORATORIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVONOLIGNAN; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; MARIN; PHOSPHATIDYLCHOLINE; SILIBININ; SILYBIN PHOSPHATIDYLCHOLINE COMPLEX; SILYMARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOGS; FEMALE; MALE; PHOSPHATIDYLCHOLINES; PHYTOTHERAPY; PLANT EXTRACTS; SILYMARIN;

CANIS FAMILIARIS; SILYBUM MARIANUM;

EID: 33847687618     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2007.00834.x     Document Type: Article

References (51)

1. Arcari, M., Brambilla, A., Brandt, A., Caponi, R., Corsi, G., Di Rella, M., Solinas, F. & Wachter, W.P. (1992) [A new inclusion complex of silibinin and beta-cyclodextrins: in vitro dissolution kinetics and in vivo absorption in comparison with traditional formulations]. Bollettino Chimico Farmaceutico, 131, 205-209.
2. Barzaghi, N., Crema, F., Gatti, G., Pifferi, G. & Perucca, E. (1990) Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. European Journal of Drug Metabolism and Pharmacokinetics, 15, 333-338.
3. Campos, R., Garrido, A., Guerra, R. & Valenzuela, A. (1989) Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Medica, 55, 417-419.
4. Center, S. (2004) Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders. Veterinary Clinics Small Animal Practice, 24, 67-172.
5. Chon, S.K. & Kim, N.S. (2005) Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs. Parasitology Research, 97, 445-451.
6. Chung, S.Y., Sung, M.K., Kim, N.H., Jang, J.O., Go, E.J. & Lee, H.J. (2005) Inhibition of P-glycoprotein by natural products in human breast cancer cells. Archives of Pharmacal Research, 28, 823-828.
7. Comoglio, A., Leonarduzzi, G., Carini, R., Busolin, D., Basaga, H., Albano, E., Tomasi, A., Poli, G., Morazzoni, P. & Magistretti, M.J. (1990) Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex. Free Radical Research Communications, 11, 109-115.
8. Crocenzi, F.A., Pellegrino, J.M., Sanchez Pozzi, E.J., Mottino, A.D., Garay, E.A. & Roma, M.G. (2000) Effect of silymarin on biliary bile salt secretion in the rat. Biochemical Pharmacology, 59, 1015-1022.
9. Dehmlow, C., Erhard, J. & de Groot, H. (1996) Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology, 23, 749-754.
10. Di Sario, A., Bendia, E., Taffetani, S., Omenetti, A., Candelaresi, C., Marzioni, M., De Minicis, S. & Benedetti, A. (2005) Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Digestive and Liver Disease, 37, 869-876.
11. Floersheim, G.L., Eberhard, M., Tschumi, P. & Duckert, F. (1978) Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicology and Applied Pharmacology, 46, 455-462.
12. Flora, K., Hahn, M., Rosen, H. & Benner, K. (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology, 93, 139-143.
13. Flory, P.J., Krug, G., Lorenz, D. & Mennicke, W.H. (1980) [Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose]. Planta Medica, 38, 227-237.
14. Fuchs, E.C., Weyhenmeyer, R. & Weiner, O.H. (1997) Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittel-Forschung, 47, 1383-1387.
15. Gatti, G. & Perucca, E. (1994) Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 32, 614-617.
16. Giacomelli, S., Gallo, D., Apollonio, P., Ferlini, C., Distefano, M., Morazzoni, P., Riva, A., Bombardelli, E., Mancuso, S. & Scambia, G. (2002) Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sciences, 70, 1447-1459.
17. Giese, L.A. (2001) Milk thistle and the treatment of hepatitis. Gastroenterology Nursing, 24, 95-97.
18. Jia, J.D., Bauer, M., Cho, J.J., Ruehl, M., Milani, S., Boigk, G., Riecken, E.O. & Schuppan, D. (2001) Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. Journal of Hepatology, 35, 392-398.
19. Jiang, C., Agarwal, R. & Lu, J. (2000) Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochemical and Biophysical Research Communications, 276, 371-378.
20. Kidd, P. & Head, K. (2005) A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Alternative Medicine Review, 10, 193-203.
21. Kren, V. & Walterova, D. (2005) Silybin and silymarin - new effects and applications. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 149, 29-41.
22. Kvasnicka, F., Biba, B., Sevcik, R., Voldrich, M. & Kratka, J. (2003) Analysis of the active components of silymarin. Journal of Chromatography. A, 990, 239-245.
23. Lorenz, D., Lucker, P.W., Mennicke, W.H. & Wetzelsberger, N. (1984) Pharmacokinetic studies with silymarin in human serum and bile. Methods and Findings in Experimental and Clinical Pharmacology, 6, 655-661.
24. Manach, C. & Donovan, J.L. (2004) Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radical Research, 38, 771-785.
25. Manach, C., Scalbert, A., Morand, C., Remesy, C. & Jimenez, L. (2004) Polyphenols: food sources and bioavailability. The American Journal of Clinical Nutrition, 79, 727-747.
26. Manach, C., Williamson, G., Morand, C., Scalbert, A. & Remesy, C. (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. The American Journal of Clinical Nutrition, 81 (Suppl.1), 230S-242S.
27. Medina, J. & Moreno-Otero, R. (2005) Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs, 65, 2445-2461.
28. Morazzoni, P., Montalbetti, A., Malandrino, S. & Pifferi, G. (1993) Comparative pharmacokinetics of silipide and silymarin in rats. European Journal of Drug Metabolism and Pharmacokinetics, 18, 289-297.
29. Mourelle, M., Muriel, P., Favari, L. & Franco, T. (1989) Prevention of CCL4-induced liver cirrhosis by silymarin. Fundamental & Clinical Pharmacology, 3, 183-191.
30. Muriel, P., Garciapina, T., Perez-Alvarez, V. & Mourelle, M. (1992) Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. Journal of Applied Toxicology, 12, 439-442.
31. Orlando, R., Fragasso, A., Lampertico, M. & Marena, C. (1991) Pharmacokinetic study of silybin-phosphatidylcholine complex in liver cirrhosis after multiple doses. Medical Science Research, 19, 827-828.
32. Paulova, J., Dvorak, M., Kolouch, F., Vanova, L. & Janeckova, L. (1990) [Verification of the hepatoprotective and therapeutic effect of silymarin in experimental liver injury with tetrachloromethane in dogs]. Veterinarni Medicina, 35, 629-635.
33. Pietrangelo, A., Montosi, G., Garuti, C., Contri, M., Giovannini, F., Ceccarelli, D. & Masini, A. (2002) Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. Journal of Bioenergetics and Biomembranes, 34, 67-79.
34. Quaglia, M.G., Bossu, E., Donati, E., Mazzanti, G. & Brandt, A. (1999) Determination of silymarine in the extract from the dried silybum marianum fruits by high performance liquid chromatography and capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis, 19, 435-442.
35. Saller, R., Meier, R. & Brignoli, R. (2001) The use of silymarin in the treatment of liver diseases. Drugs, 61, 2035-2063.
36. Schandalik, R., Gatti, G. & Perucca, E. (1992) Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittel-Forschung, 42, 964-968.
37. Silberberg, M., Morand, C., Mathevon, T., Besson, C., Manach, C., Scalbert, A. & Remesy, C. (2006) The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. European Journal of Nutrition, 45, 88-96.
38. Singh, R.P. & Agarwal, R. (2002) Flavonoid antioxidant silymarin and skin cancer. Antioxidants & Redox Signaling, 4, 655-663.
39. Singh, R.P. & Agarwal, R. (2005) Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. European Journal of Cancer, 41, 1969-1979.
40. Skottova, N., Krecman, V. & Simanek, V. (1999) Activities of silymarin and its flavanolignans upon low density lipoprotein oxidizability in vitro. Phytotherapy Research, 13, 535-537.
41. Sonnenbichler, J. & Zetl, I. (1984) Mechanism of action of silibinin. V. Effect of silibinin on the synthesis of ribosomal RNA, mRNA and tRNA in rat liver in vivo. Hoppe-Seyler's Zeitschrift Fur Physiologische Chemie, 365, 555-566.
42. Sonnenbichler, J. & Zetl, I. (1986) Biochemical effects of the flavanolignane silibinin on RNA, protein and DNA synthesis in rat livers. Progress in Clinical and Biological Research, 213, 319-331.
43. Sonnenbichler, J., Goldberg, M., Hane, L., Madubunyi, I., Vogl, S. & Zetl, I. (1986) Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochemical Pharmacology, 35, 538-541.
44. Soto, C., Mena, R., Luna, J., Cerbon, M., Larrieta, E., Vital, P., Uria, E., Sanchez, M., Recoba, R., Barron, H., Favari, L. & Lara, A. (2004) Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sciences, 75, 2167-2180.
45. Tyagi, A., Agarwal, C. & Agarwal, R. (2002) The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells. Cell Cycle, 1, 137-142.
46. Vogel, G., Tuchweber, B., Trost, W. & Mengs, U. (1984) Protection by Silymarin against Amanita phalloides intoxication in beagles. Toxicology and Applied Pharmacology, 73, 355-362.
47. Wellington, K. & Jarvis, B. (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs, 15, 465-489.
48. Weyhenmeyer, R., Mascher, H. & Birkmayer, J. (1992) Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 30, 134-138.
49. Williamson, G. & Manach, C. (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. The American Journal of Clinical Nutrition, 81 (Suppl. 1), 243S-255S.
50. Yan-Yu, X., Yun-Mei, S., Zhi-Peng, C. & Qi-Neng, P. (2006) Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. International Journal of Pharmaceutics, 319, 162-168.
51. Yanyu, X., Yunmei, S., Zhipeng, C. & Qineng, P. (2006) The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. International Journal of Pharmaceutics, 307, 77-82.